Loading...
Loading...
In a report published Tuesday, Cantor Fitzgerald analyst Irina Rivkind reiterated a Buy rating on Synergy Pharmaceuticals
SGYP, and raised the price target from $12.00 to $15.00.
In the report, Rivkind noted, “Raising PT to $15 from $12 on higher Linzess discontinuation expectations and differentiated data: After reviewing the plecanatide late-breaker abstract we have raised our revenue estimates. We believe that plecanatide can attain revenue parity with Linzess in the U.S. (based on ~30% medication disruption rates from the Linzess label, an improved tolerability profile, and an assumed big pharma partner). We summarize our model revisions in Exhibit 1 below and reiterate our BUY rating on the stock.”
Synergy Pharmaceuticals closed on Monday at $6.24.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in